

EXTEND

National Technology Transfer Biotech Hub

Technology Forum **Life Sciences 2025**

Simone Braggio

EVP, Head of Partnership Management Excellence (PME), Evotec;
Board Member EXTEND, APTADIR Therapeutics, EIR Biotherapies

An Initiative by



Fondo Nazionale Innovazione
CDP Venture Capital Ag.

Together with



evotec

Scientific promoters



Industrial promoters



Angelini
Ventures

Based in




MIND



Polo Nazionale
Trasferimento Tecnologico


Italy: strong scientific production; poor translation into value for the ecosystem

Behind other EU countries in value generation from universities innovation



Reliability
Funds/Incentives
Limited Competencies
Business Development

HIGH RISK



Note: 1. The European House - Ambrosetti: 2023

Reserved and Confidential

EXTEND

EXTEND: a Biotech hub supporting academic innovation at the national level

- Integrates **financial** and **scientific expertise** to validate discoveries
- Builds **competitive venture** models ready for investment



About Us



What We Do

We invest in **university and start-up research projects** that present therapeutic and technological innovations



Where we invest

Therapeutic areas of high unmet medical need, including Oncology, Cardiovascular, Respiratory, Genetic disorders, and CNS



Capital available:

€ 33 M; 73.5% provided by CDP VC TT Fund



Current Size:

€23.5M (+9.5 M completed by 1Q25)



Target Portfolio (3 years)

- 25 Projects
- 9 Start-ups

Portfolio to date

- 16 investment since inception
- 15 active projects in the pipeline



Linked VC Funds



Polo Nazionale Trasferimento Tecnologico



EXTEND's process

aims to **accelerate** the translation from a research project to a startup ready for IND submission and first-in-human

Identify novel therapeutic targets from academia



Identify

Leveraging **Italy's top universities and research centers**, we **identify** the next **first-in-class breakthrough therapies**

Proof-of-concept and validation in an industrial setting



Validate

In partnership with **Evotec** and through the **initial investments**, Extend **validates data in an industrial setting** and **generates additional required data** to start pre-clinical development

Startup creation with robust business models



Build

We leverage **experienced Entrepreneurs in Residence** to build **ventures** from the ground up—defining the **business case, clinical and regulatory roadmap**, and **fundraising strategy**

Support growth (fundraising, Strategic partnerships)



Co-invest

We **co-invest** in the **newly formed companies**, with follow-on participation alongside leading **venture funds**

EXTEND at a glance

€33M

Asset under management

225

Projects analysed

17

Projects and startup in portfolio

3

Milestones reached and funded

1 (2)

Startup launched

10+

Universities involved in pipeline



Aptadir Therapeutics Aptamer

Aptamer-based inhibition of DNMT-1 for **X-fragile** and **MDS**

Development stage: **lead id/optimization**




Figure 4. General MoA of DNMT1-interacting RNAs (DIRs)

PIs

A. Di Ruscio
Prof. MD PhD

T.D. Geoffrey
PhD

V. De Francis
PhD

M.T. Kortylewski
PhD

EIR


G. Amabile
PhD - CEO/Chair



Rett Syndrome Gene therapy

Restoring functionality of Mecp2 gene for the treatment of **Rett syndrome**

Development stage: **lead id/optimization**



PIs

Vania Broccoli
PhD

EIR


C. Bertozzi
PhD - CEO/Chair



RNA ToI RNA

Treatment of **heart failure** with an immunomodulating by a tolerizing modality

Development stage: **lead id/optimization**



PIs

Marinos Kallikourdis
PhD

Gianluigi Condorelli
PhD

EIR


Incoming



Imgen-T Nucleic Acid

Efficient modulation of innate immune response to nucleic acid therapeutics for **RSV- CMV**

Development stage: **lead id/optimization**



PIs

Alfredo Nicosia
PhD

Emanuele Sasso
PhD



Over 20 Professionals driving the Extend ecosystem: the key people

